Literature DB >> 21827919

Dentatorubral-pallidoluysian atrophy.

Shoji Tsuji1.   

Abstract

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder clinically characterized by various combinations of cerebellar ataxia, choreoathetosis, myoclonus, epilepsy, dementia, and psychiatric symptoms. The most striking clinical features of DRPLA are the considerable heterogeneity in clinical presentation, depending on the age of onset, and the prominent genetic anticipation. DRPLA is caused by unstable expansion of CAG repeats coding for polyglutamine stretches located in exon 5 of the DRPLA gene. DRPLA is characterized by prominent anticipation, with paternal transmission resulting in more prominent anticipation than does maternal transmission, which is now understood based on the intergenerational stability of the CAG repeats. DRPLA protein (also called atrophin-1) is localized in the nucleus and functions as a transcription co-regulator. Recent immunohistochemical studies on autopsied tissues of patients with DRPLA have demonstrated that diffuse accumulation of mutant DRPLA protein (atrophin-1) in the neuronal nuclei, rather than the formation of neuronal intranuclear inclusions (NIIs), is the predominant pathologic condition and involves a wide range of central nervous system regions far beyond the systems previously reported to be affected. Thus, age-dependent and CAG repeat-dependent intranuclear accumulation of mutant DRPLA leading to nuclear dysfunctions are suggested to be the essential pathophysiologic mechanisms in DRPLA. 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21827919     DOI: 10.1016/B978-0-444-51892-7.00041-3

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  22 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Dystonia and ataxia progression in spinocerebellar ataxias.

Authors:  Pei-Hsin Kuo; Shi-Rui Gan; Jie Wang; Raymond Y Lo; Karla P Figueroa; Darya Tomishon; Stefan M Pulst; Susan Perlman; George Wilmot; Christopher M Gomez; Jeremy D Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah H Ying; Theresa Zesiewicz; Khalaf Bushara; Michael D Geschwind; Guangbin Xia; S H Subramony; Tetsuo Ashizawa; Sheng-Han Kuo
Journal:  Parkinsonism Relat Disord       Date:  2017-10-23       Impact factor: 4.891

Review 3.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 4.  Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.

Authors:  Polina Egorova; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Semin Cell Dev Biol       Date:  2015-04-04       Impact factor: 7.727

Review 5.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 6.  Genetics of Frontotemporal Dementia.

Authors:  Diana A Olszewska; Roisin Lonergan; Emer M Fallon; Tim Lynch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

7.  Non-Ataxic Presenting Symptoms of Dominant Ataxias.

Authors:  Elsdon Storey
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 9.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

10.  DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder.

Authors:  Aiysha Chaudhry; Alkyoni Anthanasiou-Fragkouli; Henry Houlden
Journal:  J Neurol       Date:  2020-10-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.